GOLDENPOWER (03919) released its interim results, reporting a shareholder loss of HKD 9.957 million, an increase of 215.6% year-on-year.
Jinli Group (03919) announced its performance for the six months ending June 30, 2026, with revenue of HK$138 million, a year-on-year decrease of 13.2%; the company reported a loss attributable to equity shareholders of HK$9.957 million, a year-on-year increase of 215.6%; basic loss per share was HK$0.2934.
GOLDENPOWER (03919) announced its results for the six months ending June 30, 2026, with revenue of HKD 138 million, a year-on-year decrease of 13.2%; the loss attributable to equity shareholders was HKD 9.957 million, a year-on-year increase of 215.6%; and the basic loss per share was HKD 0.2934.
The loss during this period was due to (i) a decrease in revenue; (ii) a reduction in export tax rebates; (iii) the appreciation of the RMB against the HKD; and (iv) an increase in depreciation and amortization expenses.
Related Articles
KINTOR PHARMA-B (09939) released its interim results, reporting a net loss of 75.782 million yuan, a year-on-year decrease of 8.99%.
SICC Co., Ltd. (02631): It is estimated that the total impairment provision for the first half of 2026 will be 30.132 million yuan.
A-shares Evening Hotspots | Cancer Vaccine Achieves Milestone Breakthrough! Moderna Soared 150% at One Point, U.S. Pharmaceutical Stocks Explode Collectively
KINTOR PHARMA-B (09939) released its interim results, reporting a net loss of 75.782 million yuan, a year-on-year decrease of 8.99%.
SICC Co., Ltd. (02631): It is estimated that the total impairment provision for the first half of 2026 will be 30.132 million yuan.
A-shares Evening Hotspots | Cancer Vaccine Achieves Milestone Breakthrough! Moderna Soared 150% at One Point, U.S. Pharmaceutical Stocks Explode Collectively
RECOMMEND
